News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ChinaBio(R) LLC Release: The Week in Review: Fundings for China-Affiliated Drug Companies



8/12/2013 9:16:38 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

August 10, 2013 --Shenogen Pharma of Beijing raised $20 million in a Series C funding to support a Phase II trial of icaritin, an anti-cancer drug candidate; Apexigen, a California drug developer with strong connections to several China pharmas, completed a $20 million Series A1 financing; Zhongyuan Union Stem Cell Bioengineering formed a stem cell JV with Cell Therapy Ltd. of Wales; Sinopharm will gather its biotech operations into a large complex to be built in Wuhan East Lake High-tech Zone; ScinoPharm, a Taiwan CRO with expertise in process development, formed a strategic alliance with Sundia MediTech, a Shanghai CRO; Mitsubishi Tanabe Pharma will spend $19.5 million to build a new China production facility in Tianjin; Komtur Pharma, a German clinical trial sourcing company, set up a China JV with HengHeKangJian Pharma; Allium Medical of Israel signed up Beijing King Health Investment to distribute the company's urinary tract stents in China; a cross-border JV consisting of Zoetis and Jilin Guoyuan Animal Health received marketing approval in China for a new swine vaccine; and a whistleblower accused Sanofi of paying China doctors kickbacks to prescribe its blood pressure drugs. More details…

Stock Symbol: (SHA: 600645) (TAI: 1789) (TASE: ALMD) (NYSE: ZTS) (NYSE: SNY)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES